Infusion-related reactions (IRRs) associated with OCREVUS

RATES OF IRRs DURING THE OPERA TRIALS 4

IRR rates in ORATORIO were comparable to those in the OPERA I and II clinical trials.

MANAGING IRRs IN YOUR PATIENTS
Managing mild to moderate, severe, and life-threatening or disabling IRRs in your patients.
OCREVUS Dosing and Administration Guide

Download this useful resource designed to provide guidance to MS care teams and infusion centers.

Want to learn more about OCREVUS?

Sign up to speak with an OCREVUS clinical specialist.